These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 28697164)

  • 41. Intramuscular olanzapine vs. intramuscular short-acting antipsychotics: safety, tolerability and the switch to oral antipsychotic medication in patients with schizophrenia or acute mania.
    Chandrasena R; Dvoráková D; Lee SI; Loza N; Mosolov SN; Osváth P; Pregelj P; Walton RJ; Karagianis J; Treuer T
    Int J Clin Pract; 2009 Aug; 63(8):1249-58. PubMed ID: 19558486
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prehospital Agitation and Sedation Trial (PhAST): A Randomized Control Trial of Intramuscular Haloperidol versus Intramuscular Midazolam for the Sedation of the Agitated or Violent Patient in the Prehospital Environment.
    Isenberg DL; Jacobs D
    Prehosp Disaster Med; 2015 Oct; 30(5):491-5. PubMed ID: 26323511
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double-blind, placebo-controlled clinical trial.
    Chan EW; Taylor DM; Knott JC; Phillips GA; Castle DJ; Kong DC
    Ann Emerg Med; 2013 Jan; 61(1):72-81. PubMed ID: 22981685
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chronic Atypical Antipsychotic Use Is Associated With Reduced Need for Postoperative Nausea and Vomiting Rescue in the Postanesthesia Care Unit: A Propensity-Matched Retrospective Observational Study.
    Jabaley CS; Gray DW; Budhrani GS; Lynde GC; Adamopoulos P; Easton GS; O'Reilly-Shah VN
    Anesth Analg; 2020 Jan; 130(1):141-150. PubMed ID: 30585903
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A post hoc analysis of transitioning to oral treatment with olanzapine or haloperidol after 24-hour intramuscular treatment in acutely agitated adult patients with schizophrenia.
    Battaglia J; Houston JP; Ahl J; Meyers AL; Kaiser CJ
    Clin Ther; 2005 Oct; 27(10):1612-8. PubMed ID: 16330297
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prolonged extrapyramidal symptoms induced by long-term, intermittent administration of low-dose olanzapine along with metoclopramide for emesis: A case report.
    Sakamoto S; Deguchi Y; Uchida S; Itoh Y; Inoue K
    Neuropsychopharmacol Rep; 2022 Sep; 42(3):380-383. PubMed ID: 35716124
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomized Phase II Trial to Compare the Efficacy of Haloperidol and Olanzapine in the Control of Chemotherapy-Induced Nausea and Vomiting in Nepal.
    Dulal S; Paudel BD; Neupane P; Shah A; Acharya B; Poudyal BS; Shilpakar R; Wood LA
    J Glob Oncol; 2019 Apr; 5():1-6. PubMed ID: 31013182
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intramuscular olanzapine versus intramuscular haloperidol plus lorazepam for the treatment of acute schizophrenia with agitation: An open-label, randomized controlled trial.
    Huang CL; Hwang TJ; Chen YH; Huang GH; Hsieh MH; Chen HH; Hwu HG
    J Formos Med Assoc; 2015 May; 114(5):438-45. PubMed ID: 25791540
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effectiveness and safety of droperidol in a United States emergency department.
    Gaw CM; Cabrera D; Bellolio F; Mattson AE; Lohse CM; Jeffery MM
    Am J Emerg Med; 2020 Jul; 38(7):1310-1314. PubMed ID: 31831345
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A naturalistic multicenter study of intramuscular olanzapine in the treatment of acutely agitated manic or schizophrenic patients.
    San L; Arranz B; Querejeta I; Barrio S; De la Gándara J; Pérez V
    Eur Psychiatry; 2006 Dec; 21(8):539-43. PubMed ID: 16697151
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Olanzapine versus droperidol for the treatment of primary headache in the emergency department.
    Hill CH; Miner JR; Martel ML
    Acad Emerg Med; 2008 Sep; 15(9):806-11. PubMed ID: 19244630
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [A therapeutic trial in a neurology department].
    Boulliat J
    Sem Hop; 1979 Feb 18-25; 55(7-8):375-8. PubMed ID: 35833
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intravenous olanzapine--another option for the acutely agitated patient?
    Chan EW; Knott JC; Taylor DM; Phillips GA; Kong DC
    Emerg Med Australas; 2009 Jun; 21(3):241-2. PubMed ID: 19527287
    [No Abstract]   [Full Text] [Related]  

  • 54. Intramuscular olanzapine in patients with schizophrenia: an observational study in an emergency room.
    Damsa C; Adam E; Lazignac C; De Gregorio F; Mihai A; Lejeune J; Sarasin F; Allen MH
    Bull Soc Sci Med Grand Duche Luxemb; 2008; (2):209-16. PubMed ID: 18561597
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial.
    Clemmons AB; Orr J; Andrick B; Gandhi A; Sportes C; DeRemer D
    Biol Blood Marrow Transplant; 2018 Oct; 24(10):2065-2071. PubMed ID: 29906570
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Characteristics and Prevalence of Agitation in an Urban County Emergency Department.
    Miner JR; Klein LR; Cole JB; Driver BE; Moore JC; Ho JD
    Ann Emerg Med; 2018 Oct; 72(4):361-370. PubMed ID: 30031556
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An observational study of the effectiveness and safety of intramuscular olanzapine in the treatment of acute agitation in patients with bipolar mania or schizophrenia/schizoaffective disorder.
    Centorrino F; Meyers AL; Ahl J; Cincotta SL; Zun L; Gulliver AH; Kinon BJ; Houston JP
    Hum Psychopharmacol; 2007 Oct; 22(7):455-62. PubMed ID: 17708578
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A prospective, observational study of the safety and effectiveness of intramuscular psychotropic treatment in acutely agitated patients with schizophrenia and bipolar mania.
    Perrin E; Anand E; Dyachkova Y; Wagner T; Frediani S; Ballerini A;
    Eur Psychiatry; 2012 May; 27(4):234-9. PubMed ID: 20620029
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation.
    Baker RW; Kinon BJ; Maguire GA; Liu H; Hill AL
    J Clin Psychopharmacol; 2003 Aug; 23(4):342-8. PubMed ID: 12920409
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison of risperidone oral solution and intramuscular haloperidol with the latter shifting to oral therapy for the treatment of acute agitation in patients with schizophrenia.
    Fang M; Chen H; Li LH; Wu R; Li Y; Liu L; Ye M; Huang J; Zhu S; Wang G; Zhang Q; Zheng H; Zhang L; Wang B; Zhou J; Zhao JP
    Int Clin Psychopharmacol; 2012 Mar; 27(2):107-13. PubMed ID: 22233697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.